BIVICTRIX

• 72110 - Research and experimental development on biotechnology

BiVictriX is a rapidly emerging biotechnology company applying a novel approach to develop safer, more effective cancer therapies... We have developed Bi-Cygni® therapeutics, which are uniquely selective for particular cancer types, to enable higher dosing and more aggressive cancer eradication without causing harmful side effects... By combining our technology with the well-established ADC therapeutic design, we are developing a broad pipeline of next generation Bi-Cygni® ADCs with superior cancer selectivity - revolutionising how we treat patients suffering from some of the most aggressive cancers.

Also known as: BiVictriX Therapeutics, BIVICTRIX THERAPEUTICS PLC

Previous names: BIVICTRIX PLC

Registration numbers: 13470690 (CH)

Primary location: Macclesfield United Kingdom